Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1633 1732
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18792994 | AIRWAY BASAL CELL ENGRAFTMENT METHODS | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 18006009 | METHODS FOR SPERMATOGONIAL CULTURE | Non-Final OA | Washington State University |
| 17766706 | MESH CHOPPING OF NEURAL PROGENITOR CELL AGGREGATES | Non-Final OA | Cedars-Sinai Medical Center |
| 18577228 | ANIMAL MODEL FOR DISEASES ASSOCIATED WITH ABSENCE OR REDUCTION OF SOCIAL DOMINANCE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES | Non-Final OA | ADEL, Inc. |
| 18217661 | METHOD FOR MANUFACTURING STERILE BIO-INK | Non-Final OA | 3D GLOBAL BIOTECH INC. |
| 18566901 | BIOREACTOR SYSTEM WITH ENHANCED CELL HARVESTING CAPABILITIES AND RELATED METHODS | Non-Final OA | UNIVERCELLS TECHNOLOGIES SA |
| 18559936 | ISOLATED OR ARTIFICIAL NUCLEOTIDE SEQUENCES FOR USE IN NEURODEGENERATIVE DISEASES | Non-Final OA | Universidade do Algarve |
| 18557194 | COMPOSITIONS AND METHODS FOR TREATING NGYL1 DEFICIENCY | Non-Final OA | GRACE SCIENCE, LLC |
| 18546821 | METHODS OF PRODUCING HAEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Non-Final OA | ADAPTIMMUNE LIMITED |
| 17923482 | TREATMENT FOR NEURODEGENERATIVE DISEASES | Non-Final OA | UNIVERSITA DEGLI STUDI DI PADOVA |
| 17031207 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS | Non-Final OA | AQUESTIVE THERAPEUTICS, INC. |
| 17601383 | MANUFACTURING ANTI-BCMA CAR T CELLS | Non-Final OA | 2seventy bio, Inc. |
| 17464315 | METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS VIA CELL CYCLE SYNCHRONIZATION | Final Rejection | Sapphiros Al Bio LLC |
| 17310937 | METHODS OF MODULATING CD160 FUNCTION IN THE ANTIGEN-SPECIFIC IMMUNE CELL AND USES THEREOF | Final Rejection | Achelois Biopharma, Inc. |
| 17311938 | SYNTHETIC FOOD COMPOSITIONS | Final Rejection | Wild Type, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy